Atopy.

Atopy should be considered an immunological disorder that may result in several clinical conditions including respiratory disease, allergic dermatitis, food allergy dermatitis, and perhaps flea allergy dermatitis. The clinical course of the disease tends to fluctuate from season to season, which makes objective evaluation of injection therapy difficult. The disease is subject to both familial and environmental influences, and dogs maintain the atopic state throughout their life. The disease cannot be cured; however, a combination of symptomatic and specific injection therapy usually provides adequate control of the clinical signs. Owners of atopic dogs should appreciate that their pet has inherently itching skin, a cure for which is unlikely to be found.     

Gene therapy: future therapies in osteoarthritis.

The field of equine veterinary practice is in an ever-evolving state, requiring current technologies to be constantly evaluated for new applications. The specific use of gene therapy in the horse is a novel application. The authors want to help familiarize the equine practitioner with the concept of gene therapy, and introduce its use and potential future benefits for the equine industry in the treatment of osteoarthritis.     

Feeding old cats--an update on new nutritional therapies

Aging is associated with a wide variety of physiological changes that compromise the ability of the body to respond to stress or change, and ultimately contribute to morbidity and mortality. Much research has been done on the aging process in humans and experimental animals, and the impact of diet, but there is relatively little data from companion animal studies. However, although many of the aging changes are likely to be similar between different mammals, it is known that there are some differences with cats. In contrast to dogs and humans, elderly cats experience an increase in their maintenance energy requirements rather than a continued decline, which may be mediated partly through a better-maintained basal metabolic rate but also through progressive compromise in fat and protein digestion. Old age is also associated with a progressive loss of lean body mass that may be mitigated in part by feeding higher protein levels. Diets designed for healthy elderly cats should therefore concentrate on being energy dense, highly digestible and with an increase in the proportion of protein calories, and being fed with the aim of supporting optimal body weight. There is also strong evidence emerging that dietary manipulation in cats may be able to modify aspects of the aging process, with a long-term longitudinal study of cats demonstrating both survival and health benefits from feeding a diet supplemented with antioxidants, fatty acids, and a prebiotic source.     

Computational identification of new porcine microRNAs and their targets

MicroRNAs (miRNAs) represent a newly identified class of non‐protein‐coding ～22 nt small RNAs which play important roles in multiple biological processes by degrading targeted mRNAs or repressing mRNA translation. Here we present an expressed sequence tag (EST)‐based combined approach for the detection of novel porcine miRNAs. This was initiated by using previously known miRNA sequences from Homo sapiens (human) and Mus musculus (mouse) to blast the databases of Sus scrofa (pig) EST. A total of 65 new miRNAs were detected following a range of filtering criteria. Using these new potential miRNA sequences, we further obtained the publicly available porcine mRNA database from NCBI and detected 48 586 potential target hits using a software RNA hybrid. So far, compared to human and mouse, fewer miRNAs (only 54 miRNAs) were identified in Sus scrofa species. These 65 new miRNAs and their targets in pig have been run through miRHelper to yield data that may help us better understand the possible role of miRNAs in regulating the growth and development of pigs. These findings suggest that EST analysis is a good alternative strategy for identifying new miRNA candidates, their targets and other genes.     

Newer antidotal therapies.

Although the availability of an antidote for a toxic agent does not take away the primary responsibility of the clinician to manage the patient's clinical signs, the use of antidotes in appropriate situations can result in a more rapid recovery with potentially fewer long-term complications. Recent advances in pharmacology and molecular biology have resulted in the development of new and safer antidotal therapies for the management of toxicosis. The progress in immunotoxicotherapy over the last two decades continues and may ultimately lead to an era when the clinical toxicologist has a vast array of antibody fragments available for use with specific toxic agents. Development of specific pharmacologic antagonists for other agents should also enable the clinician to more reliably manage toxicoses. In spite of all these potential advances, the management of most toxicoses still relies on the application of sound veterinary medical principles.     

Marketing novel therapies.

This article discusses how to help veterinarians to (1) understand how consumers think and why they buy or do not buy something and (2) enhance their selling and marketing skills. Specific supplements and nutraceuticals are recommended, and suggestions for marketing them provided. The article emphasizes the importance of the role that veterinarians have in providing advice on the use and efficacy of supplements in their clinics when based on actual experience.     

Thromboembolic therapies in dogs and cats: an evidence-based approach.

In veterinary medicine, we are forced to make use of less than ideal "evidence," such as extrapolation from experimental studies in dogs and cats without naturally occurring diseases and from clinical trials in other species (particularly human clinical trials), as well as limited information gained from veterinary clinical experience, small clinical trials, case studies, and anecdotal reports. In this article, specific treatment recommendations are made for each of the common thromboembolic conditions seen in dogs and cats. These recommendations are made with the important caveat that, to date, such suggested therapeutic approaches are based on limited evidence.     

Natural cytotoxicity in the dog: description of two new allogeneic tumour targets

Three canine tumour cells were studied for their susceptibility to cytotoxicity by allogeneic canine natural killer (NK) cells: a lymphoma line, 3132 of B cell origin, and two adherent cell lines emanating from the same non-lymphoid tumour isolate, one (A72F) with a fibroblast morphology and one (A72E) with an epithelioid appearance. Both 3132 and A72E have preliminary evidence of retrovirus infection. Unstimulated canine peripheral blood mononuclear cells, used as the source of NK cells, were able to mediate significant lysis of 3132 and A72F cells at effector cell:target cell ratios of under 50:1, although an 18 h incubation was necessary for maximum cytotoxicity. NK activity against the 3132 tumour cells proved to be variable both within a group of dogs as well as on different occasions utilising the same individual donor. The epithelioid form of the A72 tumour cell line, A72E, had gained a marked resistance to NK lysis, although like the 3132 cells, there is preliminary evidence of persistent retrovirus infection in this cell line. Interestingly the A72F cells were as successful as homologous 3132 cells in the cold target inhibition of labelled 3132 cytotoxicity, while A72E did not. This latter result could indicate that not only do A72F and 3132 share NK determinants recognised by the same NK receptor, but the A72E line has lost this important recognition determinant.     

Superficial digital flexor tendon healing: ultrasonographic evaluation of therapies.

Until recently, it was difficult to critically evaluate tendon healing in vivo. Superficial digital flexor tendon injuries were considered healed when the injured tendon was cold, non-painful, adequate time had passed for tendon healing to occur, and no recurrence of the injury was detected when the horse returned to athletic work. This article discusses how ultrasonography has revolutionized the diagnosis, treatment, and management of tendon injuries.     

Essential Fatty Acid Supplementation In The Treatment Of Canine Atopy: A Preliminary Study

Abstract— In an open, uncontrolled study, 10 dogs with atopy were given evening primrose oil (EPO) (5ml/10kg/day) over a period of 9 weeks. During the first three weeks pruritus, scaling and oedema worsened but erythema and coat condition tended to improve. Subsequently all these parameters tended to improve. The effect on oedema was significant (p < 0.05). Eight of these dogs and two others were then given a 4:1 mixture of EPO and marine fish oil for 9 weeks. Although further reductions in scale and improvements in coat condition were marked in some animals, no significant changes occurred. Alterations in the plasma phospholipid essential fatty acid levels reflected the compositions of the two supplements. These findings suggest that EPO can ameliorate of atopy in dogs. This mirrors observations obtained in studies of human atopic eczema. Résumé— Dans une étude ouverte, sans lot témoin, 10 chiens souffrant d'atopie ont reçu de l'huile d'onagre (5 ml/10 kg/jour) pendant une période de 9 semaines. Pendant les 3 premières semaines, le prurit, le squamosis et l'oedème se sont aggravés mais, l'érythème et l'aspect du poil tendaient à s'améliorer. Enfin tous ces parametres tendaient à s'améliorer. L'effet sur l'érythème a été significatif (p < 0.05). Huit de ces chiens et deux autres ont alors reçu un mélange (4:1) d'huile d'onagre et d'huile de poisson de mer pendant 9 semaines. Bien qu'ultérieurement la diminution du squamosis et l'amélioration de l'état de la fourrure aient été manifestes chez certains animaux, il n'y eut pas de changement significatif. Les modifications des taux d'acides gras essentiels des phospholipides plasmatiques ont reflété la composition des deux supplémentations. Ces observations suggèrent que l'huile d'onagre peut apporter une amélioration de l'atopie canine. Cela reflète certains résultats observés lors d'études sur l'eczéma atopique de l'homme. Zusammenfassung— In einer offenen, nicht kontrollierten Untersuchung wurde 10 Hunden mit Atopie Nachtkerzenöl (EPO) in einer Dosierung von 5 ml/10 kg/Tag über einen Zeitraum von 9 Wochen verabreicht. Während der ersten 3 Wochen verschlimmerten sich Pruritus, Schuppenbildung und Ödeme, während Erytheme und Fellzustand eher eine Tendenz zur Besserung zeigten. Danach besserten sich alle diese Parameter. Die Wirkung auf Erytheme war signifikant (p < 0.05). Acht dieser Hunde und zwei andere erhielten 9 Wochen lang Nachtkerzenöl und Seefischöl in einer Mischung von 4:1 im Anschlufl an diese Untersuchung. Obwohl eine weitere Verminderung der Schuppenbildung und eine Vorbesserung der Fellqualität bei einigen Tieren festgestellt wurden, waren diese Veränderungen nicht signifikant. Die Veränderungen der essentiellen phospholipiden Fettsäuren im Plasma spiegeln die Zusammensetzung der beiden verabreichten Öle wieder. Diese Befunde weisen darauf hin, daß die Atopie des Hundes durch EPO gebessert werden kann. Dies entspricht auch Beobachtungen bei Untersuchungen des atopischen Exzems des Menschen.     

Essential Fatty Acid Supplementation In The Treatment Of Canine Atopy: A Preliminary Study

Abstract— In an open, uncontrolled study, 10 dogs with atopy were given evening primrose oil (EPO) (5ml/10kg/day) over a period of 9 weeks. During the first three weeks pruritus, scaling and oedema worsened but erythema and coat condition tended to improve. Subsequently all these parameters tended to improve. The effect on oedema was significant (p < 0.05). Eight of these dogs and two others were then given a 4:1 mixture of EPO and marine fish oil for 9 weeks. Although further reductions in scale and improvements in coat condition were marked in some animals, no significant changes occurred. Alterations in the plasma phospholipid essential fatty acid levels reflected the compositions of the two supplements. These findings suggest that EPO can ameliorate of atopy in dogs. This mirrors observations obtained in studies of human atopic eczema. Résumé— Dans une étude ouverte, sans lot témoin, 10 chiens souffrant d'atopie ont reçu de l'huile d'onagre (5 ml/10 kg/jour) pendant une période de 9 semaines. Pendant les 3 premières semaines, le prurit, le squamosis et l'oedème se sont aggravés mais, l'érythème et l'aspect du poil tendaient à s'améliorer. Enfin tous ces parametres tendaient à s'améliorer. L'effet sur l'érythème a été significatif (p < 0.05). Huit de ces chiens et deux autres ont alors reçu un mélange (4:1) d'huile d'onagre et d'huile de poisson de mer pendant 9 semaines. Bien qu'ultérieurement la diminution du squamosis et l'amélioration de l'état de la fourrure aient été manifestes chez certains animaux, il n'y eut pas de changement significatif. Les modifications des taux d'acides gras essentiels des phospholipides plasmatiques ont reflété la composition des deux supplémentations. Ces observations suggèrent que l'huile d'onagre peut apporter une amélioration de l'atopie canine. Cela reflète certains résultats observés lors d'études sur l'eczéma atopique de l'homme. Zusammenfassung— In einer offenen, nicht kontrollierten Untersuchung wurde 10 Hunden mit Atopie Nachtkerzenöl (EPO) in einer Dosierung von 5 ml/10 kg/Tag über einen Zeitraum von 9 Wochen verabreicht. Während der ersten 3 Wochen verschlimmerten sich Pruritus, Schuppenbildung und Ödeme, während Erytheme und Fellzustand eher eine Tendenz zur Besserung zeigten. Danach besserten sich alle diese Parameter. Die Wirkung auf Erytheme war signifikant (p < 0.05). Acht dieser Hunde und zwei andere erhielten 9 Wochen lang Nachtkerzenöl und Seefischöl in einer Mischung von 4:1 im Anschlufl an diese Untersuchung. Obwohl eine weitere Verminderung der Schuppenbildung und eine Vorbesserung der Fellqualität bei einigen Tieren festgestellt wurden, waren diese Veränderungen nicht signifikant. Die Veränderungen der essentiellen phospholipiden Fettsäuren im Plasma spiegeln die Zusammensetzung der beiden verabreichten Öle wieder. Diese Befunde weisen darauf hin, daß die Atopie des Hundes durch EPO gebessert werden kann. Dies entspricht auch Beobachtungen bei Untersuchungen des atopischen Exzems des Menschen.     

Current therapies in exotic animal oncology.

The majority of information on oncology therapies has been reported in humans, canine, and feline patients, and laboratory animals with experimentally induced tumors. A variety of treatments,including radiation therapy, chemotherapy, photodynamic therapy, and others have been used with exotic animals. There are many species of exotic pets, and anatomic differences, as well as husbandry and nutritional requirements, must be taken into account to provide optimal care. By providing a broad overview of therapies and considerations for treatment, this article is intended to provide the practitioner with an overview of approach and options when addressing oncology cases in exotic animals.     

Systemic therapies for joint disease in horses.

Systemic therapies for joint disease may be prescribed when a single joint is involved or when multiple sites are affected. The precise therapeutic regimen recommended depends on the duration,cause, and site(s) of injury and is often an adjunct to intra-articular or supportive therapies. If the clinical signs of joint disease are acute and moderate in severity, nonsteroidal anti-inflammatory drugs are often administered to alleviate pain and inflammation.When aiming for more of a generalized maintenance or chondro-protective regimen, an alternative medication, such as hyaluronan,polysulfated glycosaminoglycan, or a nutraceutical will commonly be prescribed.     

Identifying innate immune pathways of the chicken may lead to new antiviral therapies

Fractalkine, also known as CX(3)CL1, is a unique chemokine that mediates inflammatory responses and is involved in the pathogenesis of several inflammatory disorders, including inflammatory bowel disease (IBD) in humans. In this study, we isolated cDNAs encoding canine fractalkine and its receptor CX(3)CR1, and assessed the biological activity of these molecules. The deduced amino acid sequence of the canine fractalkine cDNA showed 66% and 57% identity to human and mouse homologs, respectively. The N-terminal chemokine domain of the canine fractalkine showed 68% and 65% identity to human and mouse counterparts, respectively. The canine CX(3)CR1 amino acid sequence showed close homology to its human (83% identity) and mouse (81% identity) counterparts. Fractalkine and CX(3)CR1 mRNA were detected in all tissues in this study. Relatively higher expression levels of fractalkine mRNA were observed in the brain, medulla spinalis, small intestine, and mesenteric lymph nodes (MLNs), whereas higher expression levels of CX(3)CR1 mRNA were observed in the medulla spinalis, brain, liver, small intestine, and MLNs. The cross-reactivities of anti-human fractalkine antibody and anti-rat CX(3)CR1 antibody to canine proteins were confirmed using recombinant canine fractalkine and a cell line overexpressing canine CX(3)CR1, respectively. A transwell chemotaxis assay showed that the recombinant canine fractalkine induced migration in canine lymphoid cells expressing CX(3)CR1. The present study will be useful in understanding the canine immune system and the immunopathogenesis of canine inflammatory diseases.